Any current/future capex/capital investment/strategic investment?

Currently, there are no immediate plans for new capital expenditure (capex) or expansions. The company has already completed expansions in the last one and a half years using a mix of debt and internal accruals. A proposed Follow-on Public Offer (FPO) intended to raise capital is currently on hold. The focus remains on utilizing existing capacities effectively rather than committing to fresh large-scale investments in the near term.

Future growth expectations in sales/revenue/volumes?

Demand outlook is optimistic from Q4 FY23 and into FY24, with inquiries increasing significantly since January. Growth is expected to be better than FY22 and FY23, driven by improving demand in India and export markets. Expansion in chemical, pharmaceutical, agrochemical sectors is expected to boost growth. Exports, especially in hospital furniture segment, show promise with growing inquiries but no current exports. New client addition: 25-30 new clients added in last 6 months, mainly in plastic packaging. Capacity utilization currently at around 65%, with scope for improvement as demand picks

Future growth expectations in earnings/operating earnings/profits/EPS?

The management is optimistic about FY24, expecting much better performance than FY22 and FY23. Demand outlook from January 2023 is picking up strongly with increased inquiries converting into business. Positive growth seen across sectors with better utilization expected in Q4 FY23 and beyond. Repeat business is strong, with 80% revenue from about 50 clients, many being Fortune 500 companies, indicating stable earnings. EBITDA margins expected to improve sequentially from Q4 FY23 as high-cost inventory gets exhausted. Expansion plans on hold currently, but internal accruals and debt financing h

Current/ Expected Orderbook/ Pending Orders?

The company has added around 25 to 30 new clients in the last 6 months, indicating a growing order book. Approximately 80% of the business comes from about 50 companies, with 45 to 50 companies providing repeat orders annually, showing a stable and recurring order flow. Inquiry levels have picked up significantly from January, translating into many new inquiries and potential converts into business. New orders are notably from plastic packaging, hospital furniture segments, and emerging export markets. The company is optimistic about onboarding many more clients going forward. No specific info

Any current/future new fundraising through debt or equity?

Currently, there are no plans for new CAPEX or fundraising through debt or equity. The company has recently expanded using debt and internal accruals. There was a mention of a future Follow-on Public Offer (FPO), but it is currently on hold. No additional debt or equity raising is planned at this moment.

IN US

Sale is live|00:00:00left today

Mitsu Chem Plast LtdQ4 FY24Industrial Products

Mitsu Chem Plast Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹151P/E: 9.6Market Cap: ₹151 CrSector: Industrial Products

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

Order

Yes

Capex

1 of 5 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Demand outlook is optimistic from Q4 FY23 and into FY24, with inquiries increasing significantly since January.
→Growth is expected to be better than FY22 and FY23, driven by improving demand in India and export markets.
→Expansion in chemical, pharmaceutical, agrochemical sectors is expected to boost growth.
→Exports, especially in hospital furniture segment, show promise with growing inquiries but no current exports.
→New client addition: 25-30 new clients added in last 6 months, mainly in plastic packaging.
→Capacity utilization currently at around 65%, with scope for improvement as demand picks up.
→Company is optimistic about entering sustainable packaging and recycling initiatives, which may spur future growth.
→Expected sequential improvement in margins from Q4 due to normalization of polymer prices and better product mix.
→Capital expenditure plans are on hold currently; expansion done in last 1.5 years funded through debt and internal accruals.

Margin guidance

Category 2

→The management is optimistic about FY24, expecting much better performance than FY22 and FY23.
→Demand outlook from January 2023 is picking up strongly with increased inquiries converting into business.
→Positive growth seen across sectors with better utilization expected in Q4 FY23 and beyond.
→Repeat business is strong, with 80% revenue from about 50 clients, many being Fortune 500 companies, indicating stable earnings.
→EBITDA margins expected to improve sequentially from Q4 FY23 as high-cost inventory gets exhausted.
→Expansion plans on hold currently, but internal accruals and debt financing have supported past expansions.
→Growth drivers include increasing demand in plastic packaging, hospital furniture, and new technical products.
→Focus on sustainability and innovative products aims to enhance product mix and profitability.
→Overall outlook for FY24 and FY25 is bullish with expected significant improvement in top-line and profitability.

3 more insights locked — sign up free to unlock

Fundraise plans

→Currently, there are no plans for new CAPEX or fundraising through debt or equity.
→The company has recently expanded using debt and internal accruals.
→There was a mention of a future Follow-on Public Offer (FPO), but it is currently on hold.
→No additional debt or equity raising is planned at this moment.

Order book

Yes

→The company has added around 25 to 30 new clients in the last 6 months, indicating a growing order book.
→Approximately 80% of the business comes from about 50 companies, with 45 to 50 companies providing repeat orders annually, showing a stable and recurring order flow.
→Inquiry levels have picked up significantly from January, translating into many new inquiries and potential converts into business.
→New orders are notably from plastic packaging, hospital furniture segments, and emerging export markets.
→The company is optimistic about onboarding many more clients going forward.
→No specific information on the total value or backlog of pending orders was disclosed, but improvement in inquiries and customer additions point to a positive order pipeline.

Capex plans

→Currently, there are no immediate plans for new capital expenditure (capex) or expansions.
→The company has already completed expansions in the last one and a half years using a mix of debt and internal accruals.
→A proposed Follow-on Public Offer (FPO) intended to raise capital is currently on hold.
→The focus remains on utilizing existing capacities effectively rather than committing to fresh large-scale investments in the near term.

How does Mitsu Chem Plast Ltd rank vs peers in Industrial Products?

Pro feature

1Mitsu Chem Plast Ltd

Rev 3Mar 2

See full Industrial Products sector rankings

Want more stocks like Mitsu Chem Plast Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio